

PMX Publication List 2018

No	Title	Author	Country	Journal	study type
2018-1	pH after the first session of direct hemoperfusion with polymyxin B-immobilized fibers predicts mortality in patients with sepsis and septic shock	Okubo A et al.	Japan	Clin Exp Nephrol. (2018) Feb. 24	observational study
2018-2	Septic shock from descending necrotizing mediastinitis – combined treatment with IgM-enriched immunoglobulin preparation and direct polymyxin B hemoperfusion: a case report	Pota V et al.	Italy	J Med Case Rep (2018) 12:55	case report
2018-3	Sphingosine-1-Phosphate (S1P) Is a Feasible Biomarker in Predicting the Efficacy of Polymyxin B-Immobilized Fiber Direct Hemoperfusion (PMX-DHP) in Patients with Septic Shock	Inoue S et al.	Japan	J Nippon Med Sch (2018) 85:39-46	observational study
2018-4	Heparin dosing score protocol for anticoagulation during polymyxin B hemoperfusion	Lee CT et al.	Taiwan	J Formos Med Assoc (2018) Mar 16	observational study
2018-5	Regional citrate-calcium anticoagulation during polymyxin-B hemoperfusion: A case series	Forfori F et al.	Italy	Int J Artif Organs (2018) Mar 26	case series
2018-6	Extended Sessions of Polymyxin-B Immobilized Fiber Column Hemoperfusion Ameliorate Renal Outcome and Mortality in Septic Shock with Acute Kidney Injury	Maekawa H et al.	Japan	Blood Purif. (2018)46:81-89	observational study
2018-7	In vitro comparison of the adsorption of inflammatory mediators by blood purification devices.	Malard B et al.	France	Intensive Care Med Exp (2018) 6:12	in vitro experiment
2018-8	In Vitro Study of Endotoxin Adsorption by a Polymyxin B-Immobilized Fiber Column.	Yamashita C et al.	Japan	Blood Purif (2018) 46:269-73	in vitro experiment
2018-9	Impact of polymyxin B hemoperfusion in the treatment of patients with sepsis and septic shock: a meta-analysis of randomized controlled trials.	Kuriyama A et al.	Japan	Ann Transl Med (2018) 6:206	Systematic review
2018-10	Evidence and Perspectives on the Use of Polymyxin B-Immobilized Fiber Column Hemoperfusion among Critically Ill Patients.	Yamashita C et al.	Japan	Contib Nephrol (2018) 196:215-22	review
2018-11	Mortality Effects of Prolonged Hemoperfusion Therapy Using a Polymyxin B-Immobilized Fiber Column for Patients with Septic Shock: A Sub-Analysis of the DESIRE Trial	Kawazoe Y et al.	Japan	Blood Purif (2018) 46:309–14	observational study
2018-12	Efficacy of polymyxin B hemoperfusion in and beyond septic shock: is an “endotoxin severity score” needed?.	Honore PM et al.	Belgium	Crit Care (2018) 22:205	comment
2018-13	Clinical Effects of Polymyxin B Hemoperfusion in Patients With Septic Shock Caused by Urinary Tract Infection	Suzuki Y et al.	Japan	Ther Apher Dial. 2018 Sep 12	case series
2018-14	Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.	Dellinger RP et al.	USA	JAMA (2018) 320:1455-63	multi-center RCT
2018-15	The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients	Srisawat N	Thailand	Crit Care (2018) 22:279	RCT
2018-16	Study of High Mobility Group Box 1 Values in Septic Disseminated Intravascular Coagulation Treated by Polymyxin-B Immobilized Fiber-Direct Hemoperfusion.	Takahashi G et al.	Japan	J Bacteriol Parasitol (2018) 9:1000346	observational study
2018-17	Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial	Klein DJ. et al.	Canada	Intensive Care Med (2018) Nov.23	multi-center RCT
2018-18	Treatment with a polymyxin B filter to capture endotoxin in sepsis patients: is there a signal for therapeutic efficacy	Pickkers P et al.	Netherlands	Intensive Care Med (2018) Dec 3	comment
2018-19	Impact of hemoperfusion with polymyxin B added to hemofiltration in patients with endotoxic shock: a case-control study	Navas A et al.	Spain	Ann. Intensive Care (2018) 8:121	observational study